{"id":5115,"date":"2025-11-04T21:28:58","date_gmt":"2025-11-04T18:28:58","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=5115"},"modified":"2025-11-05T00:18:00","modified_gmt":"2025-11-04T21:18:00","slug":"sarepta-dmd-exon-skipping-therapies-fail-confirmatory-study-stock-price-down","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/es\/sarepta-dmd-exon-skipping-therapies-fail-confirmatory-study-stock-price-down\/","title":{"rendered":"Las terapias de Sarepta para la distrofia muscular de Duchenne (DMD) basadas en el salto de exones fracasan en un estudio confirmatorio; el precio de las acciones cae."},"content":{"rendered":"<p class=\"wp-block-paragraph\">Las dificultades relacionadas con el gen Sarepta Therapeutics solo empeoran. En pacientes con distrofia muscular de Duchenne, la empresa descubri\u00f3 que sus tratamientos de omisi\u00f3n de exones, Vyondys 53 y Amondys 45, no mejoraron significativamente la funci\u00f3n motora. <a href=\"https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-third-quarter-2025-financial\" target=\"_blank\" rel=\"noreferrer noopener\">Anuncio de Sarepta<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">En las operaciones previas a la apertura del martes, la empresa biotecnol\u00f3gica se vendi\u00f3 a $15,60, una disminuci\u00f3n de 36% con respecto al precio de cierre de las acciones del lunes de $24,45.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Los analistas de William Blair escribieron en una carta a sus clientes el martes por la ma\u00f1ana que los resultados de los ensayos cl\u00ednicos de los medicamentos generaban dudas sobre su futuro, a pesar del optimismo de Sarepta. A\u00f1adieron: \u2019Consideramos que la incapacidad del ensayo ESSENCE para lograr su objetivo principal es un hecho negativo\u201c.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Aunque la direcci\u00f3n est\u00e1 segura de que Vyondys 53 y Amondys 45 no perder\u00e1n su autorizaci\u00f3n de comercializaci\u00f3n como resultado, seguimos teniendo dudas y creemos que la reacci\u00f3n de las acciones (con una ca\u00edda de 37% despu\u00e9s del cierre) indica que los inversores tambi\u00e9n est\u00e1n preocupados por el futuro de estos dos medicamentos.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Sigue esta p\u00e1gina<\/strong>&nbsp;&gt;&gt;&gt;&nbsp;<a href=\"https:\/\/dmdwarrior.com\/es\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Todos los ensayos cl\u00ednicos para la distrofia muscular de Duchenne<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Sarepta Therapeutics&#8217; difficulties only get worse. In patients with Duchenne muscular dystrophy, the business found that their exon-skipping treatments, Vyondys 53 and Amondys 45, did not considerably enhance motor function. >>> Sarepta Announcement Tuesday&#8217;s pre-market trading saw the biotech selling at $15.60, a 36% decrease from Monday&#8217;s closing share price of $24.45. William Blair analysts [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5117,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[453,77,178,65,394],"class_list":["post-5115","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-amondys-45","tag-exon-skipping","tag-exon-skipping-therapies","tag-sarepta","tag-vyondys-53"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/5115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=5115"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/5115\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/5117"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=5115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=5115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=5115"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}